A

ABL Bio Inc
KOSDAQ:298380

Watchlist Manager
ABL Bio Inc
KOSDAQ:298380
Watchlist
Price: 27 400 KRW 3.79% Market Closed
Market Cap: 1.3T KRW
Have any thoughts about
ABL Bio Inc?
Write Note

ABL Bio Inc
EPS (Diluted)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ABL Bio Inc
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
A
ABL Bio Inc
KOSDAQ:298380
EPS (Diluted)
-â‚©747
CAGR 3-Years
13%
CAGR 5-Years
36%
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
EPS (Diluted)
â‚©907
CAGR 3-Years
-38%
CAGR 5-Years
-13%
CAGR 10-Years
2%
SK Bioscience Co Ltd
KRX:302440
EPS (Diluted)
â‚©289
CAGR 3-Years
-18%
CAGR 5-Years
15%
CAGR 10-Years
N/A
H
Hugel Inc
KOSDAQ:145020
EPS (Diluted)
â‚©9.9k
CAGR 3-Years
26%
CAGR 5-Years
22%
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
EPS (Diluted)
â‚©8.4k
CAGR 3-Years
21%
CAGR 5-Years
32%
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
EPS (Diluted)
-â‚©54
CAGR 3-Years
51%
CAGR 5-Years
22%
CAGR 10-Years
N/A
No Stocks Found

ABL Bio Inc
Glance View

Market Cap
1.3T KRW
Industry
Biotechnology

ABL Bio, Inc. engages in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2018-12-19. The major products include anti-angiogenesis antibodies anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, antibody-drug conjugates (ADCs) , among others.

Intrinsic Value
8 401.38 KRW
Overvaluation 69%
Intrinsic Value
Price
A

See Also

What is ABL Bio Inc's EPS (Diluted)?
EPS (Diluted)
-747 KRW

Based on the financial report for Jun 30, 2024, ABL Bio Inc's EPS (Diluted) amounts to -747 KRW.

What is ABL Bio Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
36%

Over the last year, the EPS (Diluted) growth was -8%. The average annual EPS (Diluted) growth rates for ABL Bio Inc have been 13% over the past three years , 36% over the past five years .

Back to Top